Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Nonalcoholic Fatty Liver Disease (Version 3.0)

Inclusion Criteria: * Patients diagnosed with type 2 diabetes and NAFLD. * Age between 18 and 75 years. * Body mass index (BMI) \> 18.0 kg/m2 * Weight stable for at least 3 months prior to the study (gain or loss \<4kg). * Stable treatment for at least 3 months with 1-3 oral * antidiabetic medications (with or without insulin therapy), or not yet receiving antidiabetic medication prior to the beginning of the study. * Able to give written informed consent. Exclusion Criteria: * Participants meeting any of the following criteria will not be allowed to participate in the trial: * Use of any of the following medications or treatments: * Use of other medications that may affect glucose metabolism within the past 2 months, including systemic glucocorticoids (excluding inhaled or topical use), growth hormones, etc.; * Use of antihypertensive or lipid-lowering medications that have not reached a stable dosage before screening; * Presence of any of the following medical histories or conditions: * History or presence of any cardiac disease within the past 6 months; * Decompensated heart failure (NYHA Class III or IV); * Unstable angina, myocardial infarction, coronary artery bypass grafting, or coronary stenting; * Uncontrolled or severe arrhythmias (e.g., long QT syndrome), as assessed by the investigator as unsuitable for trial participation; * History of hemorrhagic or ischemic stroke within the past 6 months, as assessed by the investigator as unsuitable for trial participation; * Medical history of cerebral thrombosis, cerebral vascular blockage, encephalic angioma, transient ischemic attack, cerebral hemorrhage, stroke, hydrocephalus, or malignant brain tumor; * History of carotid artery stenting; * Urinary system conditions such as nephrotic syndrome, uremia, polycystic kidney disease, kidney transplantation, unilateral nephrectomy/congenital solitary kidney, renal atrophy, renal tumor; * Digestive system conditions such as ascites, liver cirrhosis, liver fluke infection, severe hepatitis, gastric varices; * Nervous system conditions such as cerebellar atrophy, demyelinating diseases, cerebral palsy, Parkinson's disease, mania, schizophrenia; * Respiratory system conditions such as pulmonary embolism, cor pulmonale; * Musculoskeletal system conditions such as arterial rupture, myeloma; * Immune system conditions such as Behçet's disease, lupus erythematosus; * Conditions such as chondrosarcoma, liposarcoma, brucellosis, leukemia; * History of malignant tumor within the past 5 years, or currently under evaluation for potential malignancy; * History of unstable or treatment-requiring proliferative retinopathy or macular edema within the past 6 months; * History of diabetic ketoacidosis or hyperosmolar nonketotic diabetic coma within the past 6 months; * Currently suffering from lower extremity arteriosclerotic occlusive disease; History of severe infection or severe trauma within the past 1 month; * History of ≥2 severe hypoglycemic episodes within the past year; * Currently suffering from clinically significant urinary tract/genital infection, or a history of complicated urinary tract infections, or recurrent urinary tract infections within the past 6 months; * Currently suffering from uncontrolled hypertension, defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg at screening/baseline, or systolic blood pressure ≤90 mmHg and/or diastolic blood pressure ≤60 mmHg; * Currently suffering from uncontrolled thyroid dysfunction; * History of other severe endocrine diseases, such as multiple endocrine neoplasia; * History of severe hepatic or renal disease; * Suspected or confirmed history of alcohol or drug abuse; * Blood donation or blood loss ≥400 mL within the past 3 months; * Presence of severe psychiatric disorders or language barriers, unwillingness or inability to fully understand and cooperate; * Pregnant or breastfeeding women; * Any other conditions deemed unsuitable for trial participation by the investigator.